Cynomolgus CD20 / MS4A1 Full Length Protein, His Tag

Source : 

Cynomolgus CD20 Full Length, His Tag (CD0-C52H8) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # M4ZHZ6-1 ).

 

Molecule : CD20

 

Synonyms : MS4A1,CD20,MS4A-1

 

Format : Liquid

 

Category : Bio-Markers & CD Antigens

 

Accession : NP_001274241.1

 

Storage : -70℃

 

Shipping condition : Liquid,-70℃Dry ice

 

Molecular Weight : 35.2 kDa

 

Characteristics :

This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 35.2 kDa. The protein migrates as 36-38 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5

 

Description :

B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

 

References :

(1) Walport M, et al., 2008, Janeway's Immunobiology (7th ed.). New York: Garland Science.
(2) Bonilla FA, Bona CA., 1996, Textbook of Immunology. Boca Raton: CRC. p. 102.
(3) Cragg MS., 2005., Curr. Dir. Autoimmun. 8: 140–74.